{"nctId":"NCT01371825","briefTitle":"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency","startDateStruct":{"date":"2011-05-04","type":"ACTUAL"},"conditions":["Lysosomal Acid Lipase Deficiency","Wolman Disease"],"count":9,"armGroups":[{"label":"Open-Label Sebelipase Alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Sebelipase alfa (SBC-102)"]}],"interventions":[{"name":"Sebelipase alfa (SBC-102)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant's parent or legal guardian provided written informed consent/permission prior to any study procedures.\n* Male or female child with documented decreased LAL activity relative to the normal range of the laboratory performing the assay or documented result of molecular genetic testing (2 mutations) confirming a diagnosis.\n* Growth failure with onset before 6 months of age.\n\nExclusion Criteria:\n\n* Clinically important concurrent disease or comorbidities.\n* Had received an investigational product other than sebelipase alfa within 14 days prior to the first dose.\n* Participant was older than 24 months of age.\n* Myeloablative preparation, or other systemic pre-transplant conditioning, for hematopoietic stem cell or liver transplant.\n* Previous hematopoietic stem cell or liver transplant.\n* Known hypersensitivity to eggs.","healthyVolunteers":false,"sex":"ALL","maximumAge":"24 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of Age","description":"The primary efficacy endpoint was the percentage of participants (%) in the PES who survived to at least 12 months of age.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Of Participants Surviving Beyond 12 Months Of Age","description":"The percentage of participants in the PES who survived to at least 18 months of age.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Age At Death","description":"Participants in the PES who died during the study, including 3 participants who died after having received between 1 and 4 infusions of sebelipase alfa and 1 participant who died after approximately 40 weeks on treatment.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline To Months 12, 24, 36, 48, And 60 In Weight For Age (WFA) Percentiles","description":"Baseline is defined as the last measurement prior to the first infusion of sebelipase alfa.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.469","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.787","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.037","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.770","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.869","spread":null}]}]}]},{"type":"SECONDARY","title":"Number Of Participants With Stunting, Wasting, Or Underweight","description":"The number of participants who met criteria for the following dichotomous indicators of under nutrition were reported. These indicators included the following:\n\n* Stunting was defined as at least 2 standard deviations below the median for length-for-age/height-for-age;\n* Wasting was defined as wasting at least 2 standard deviations below the median for weight-for-length/weight-for-height; and\n* Underweight was defined as at least 2 standard deviations below the median for WFA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Transaminases (ALT And AST)","description":"Change from Baseline to Months 12, 24, 36, 48, and 60 for alanine aminotransferase (ALT) and aspartate aminotransferase (AST).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Ferritin","description":"The median change in serum ferritin from Baseline to Months 12, 24, 36, 48, and 60 is presented.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-294.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-239.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-262.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-268.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-213.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization [TFHN]","description":"The number of participants achieving and maintaining TFHN are presented.\n\nFor TFHN to be achieved, the participant must a) have had 2 post-baseline measurements of hemoglobin at least 4 weeks apart that were both above the age-adjusted lower limit of normal; b) have had no known additional measurements of hemoglobin that were below the age-adjusted lower limit of normal during the (minimum) 4-week period; and c) have had no transfusions during the (minimum) 4-week period, and also no transfusions for 2 weeks prior to the first hemoglobin measurement in the (minimum) 4-week period.\n\nFor TFHN to be maintained, the participant must have been transfusion-free beginning at Week 6 and had all hemoglobin assessments above the lower limit of normal beginning in Week 8 and lasting at least 13 weeks.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":9},"commonTop":["Vomiting","Diarrhoea","Pyrexia","Rhinitis","Nasopharyngitis"]}}}